Jenburkt Pharmaceuticals launches antiviral drug 'Favipiravir' to fight COVID-19

25 Jul 2020 Evaluate

Jenburkt Pharmaceuticals has launched antiviral drug Favipiravir (brand name Favivent) for the treatment of mild to moderate COVID-19 symptoms at a price of Rs 39 per tablet. This is not the first foray into timely, rapid innovation from the Jenburkt stable. This innovation-driven organisation was the first in the world to introduce Nervijen, Metmin-A, Powergesic, Infartin and a few more, across multiple therapeutic areas. The company’s R&D unit, approved by the Ministry of Science & Technology, Government of India, is their gateway to health through innovation.

Jenburkt is the second in India to introduce Favipiravir (brand name Favivent) for the treatment of COVID-19. Favivent is manufactured at a pharmaceutical plant which is compliant with US-FDA (U. S. Food and Drug Administration) and EDQM (The European Directorate for the Quality of Medicines & HealthCare) standards located in the state of Telangana, with the highest safety and manufacturing protocols in place. According to Jenburkt, the medication will be available in the form of 1 strip of 10 tablets.

Jenburkt Pharmaceuticals is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.

Jenburkt Pharma Share Price

1089.55 9.55 (0.88%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×